Explore

IT STARTS WITH

RECOGNISING PEOPLE LIVING WITH HIV WHO EXPERIENCE CHALLENGES WITH REGULAR DAILY ORAL THERAPY

While significant advancements have been made in HIV treatment, People Living with HIV (PLHIV) in your practice may be experiencing challenges with their regular daily oral therapy.[1–3]

sherri

Reflecting on taking regular daily oral therapy

"Mentally, you know, I was stuck on taking a medicine everyday for the rest of my life."

SHERRI, LIVING WITH HIV.

Receiving every-2-month VOCABRIA + REKAMBYS.

marvin

Fear of disclosure

“I didn't want anyone to know, anyone to find out. And so my medicine cabinet was my glove compartment in my car.”

MARVIN, LIVING WITH HIV.

Receiving every-2-month VOCABRIA + REKAMBYS.

jorge

The daily reminder

“It was just this daily reminder that played a huge role in my medical condition”

JORGE, LIVING WITH HIV.

Receiving every-2-month VOCABRIA + REKAMBYS.

Josh

Journey with HIV and treatments

"Pills were always a reminder of my status and a realisation that I had an incurable disease which would effect the rest of my life."

JOSH, LIVING WITH HIV.

Receiving every-2-month VOCABRIA + REKAMBYS.

Reflection form PLHIV

Reflections from people living with HIV

Hear from some people living with HIV reflect on their personal experiences

Switching from a regular daily oral therapy to a every-2-month VOCABRIA + REKAMBYS.

Challenges revealed by SOLAR patients on daily oral therapy with BIC/FTC/TAF at baseline[1]

of participants on daily oral therapy with BIC/FTC/TAF (n=315/670) reported always or often experiencing at least one of the following challenges:[1]

  • Worried about people unintentionally discovering their HIV status
  • Worried about forgetting to take their HIV medication
  • Felt that taking their HIV medication was an uncomfortable reminder of their HIV status

  • Other global studies surveying PLHIV and physicians

    Other global studies surveyed people living with HIV and physicians on a variety of daily oral regimens and highlighted challenges they face[2-4]

    Positive Perspectives 2 was one of the largest global HIV patient-reported outcomes studies to date. A total of 2,389 people living with HIV aged ≥18 years across 25 countries took part in the study.[2] The impact of emotional challenges was confirmed again by physicians (n=120) and people living with HIV (n=698) in a multinational study across four European countries.[4] The studies were funded by ViiV Healthcare.[2−4]

Discover what trial patients think about a complete long-acting regimen

Contact us for support

ARV=antiretroviral; BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; HIV=human immunodeficiency virus; PLHIV=people living with HIV.

References:

  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4
  2. de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: Findings from the Positive Perspectives Study. AIDS Behav. 2021;25(3):961−972. doi: 10.1007/s10461-020-03055-1.
  3. Clark L, Karki C, Noone J, et al. Quantifying people living with HIV who would benefit from an alternative to daily oral therapy: Perspectives from HIV physicians and people living with HIV. Popul Med. 2020;2:33. doi: 10.18332/popmed/126632.
  4. Data on file. CARLA EU Unmet Need Study HO-20-9637. REF-180204. ViiV Healthcare group of companies.

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-230016 | January 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.